CLNN Stock Overview
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
+ 2 more risks
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.63|
|52 Week High||US$8.60|
|52 Week Low||US$1.93|
|1 Month Change||-19.33%|
|3 Month Change||63.51%|
|1 Year Change||-50.14%|
|3 Year Change||-64.72%|
|5 Year Change||n/a|
|Change since IPO||-62.38%|
Recent News & Updates
Clene ALS therapy gets EMA panel backing for orphan drug status
A panel of the European Medicines Agency (EMA) recommended granting orphan drug designation to Clene (NASDAQ:CLNN) CNM-Au8 to treat amyotrophic lateral sclerosis (ALS). The EMA's Committee for Orphan Medicinal Products (COMP) decision was was backed by data from a phase 2 trial called RESCUE-ALS and preclinical ALS models, the company said in a July 19 press release. ALS is a progressive nervous system disease affecting the nerve cells in the brain and spinal cord, causing loss of muscle control. In EU the orphan drug status is given to therapies aimed at treating a serious or life-threatening disease affecting not more than five in 10K people in the EU. The designation has benefits, including 10 years of market exclusivity, if approved. CLNN -4.97% to $4.59 premarket July 19
|CLNN||US Biotechs||US Market|
Return vs Industry: CLNN underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: CLNN underperformed the US Market which returned -9.6% over the past year.
|CLNN Average Weekly Movement||20.9%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CLNN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: CLNN's weekly volatility has increased from 15% to 21% over the past year.
About the Company
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company’s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications.
Clene Fundamentals Summary
|CLNN fundamental statistics|
Is CLNN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLNN income statement (TTM)|
|Cost of Revenue||-US$509.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.24|
|Net Profit Margin||4,138.77%|
How did CLNN perform over the long term?See historical performance and comparison
Is CLNN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLNN?
Other financial metrics that can be useful for relative valuation.
|What is CLNN's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CLNN's PE Ratio compare to its peers?
|CLNN PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
LJPC La Jolla Pharmaceutical
MREO Mereo BioPharma Group
SESN Sesen Bio
Price-To-Earnings vs Peers: CLNN is good value based on its Price-To-Earnings Ratio (14.9x) compared to the peer average (18x).
Price to Earnings Ratio vs Industry
How does CLNN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: CLNN is good value based on its Price-To-Earnings Ratio (14.9x) compared to the US Biotechs industry average (16x)
Price to Earnings Ratio vs Fair Ratio
What is CLNN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||14.9x|
|Fair PE Ratio||66.2x|
Price-To-Earnings vs Fair Ratio: CLNN is good value based on its Price-To-Earnings Ratio (14.9x) compared to the estimated Fair Price-To-Earnings Ratio (66.2x).
Share Price vs Fair Value
What is the Fair Price of CLNN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CLNN ($3.63) is trading below our estimate of fair value ($131.38)
Significantly Below Fair Value: CLNN is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Clene forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLNN's forecast earnings growth (85% per year) is above the savings rate (1.9%).
Earnings vs Market: CLNN's earnings (85% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: CLNN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CLNN's revenue (83.3% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CLNN's revenue (83.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLNN is forecast to be unprofitable in 3 years.
Discover growth companies
How has Clene performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLNN has a large one-off gain of $66.0M impacting its June 30 2022 financial results.
Growing Profit Margin: CLNN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CLNN has become profitable over the past 5 years, growing earnings by 24.8% per year.
Accelerating Growth: CLNN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CLNN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: CLNN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Clene's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CLNN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CLNN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CLNN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CLNN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: CLNN's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if CLNN's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is Clene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLNN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLNN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLNN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CLNN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rob Etherington (55 yo)
Mr. Robert Etherington, also known as Rob, MBA, serves as President, Chief Executive Officer and Director at Clene Inc. since April 2013. He serves as the Chief Executive Officer and President of Clene Nan...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD5.10M) is above average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
Experienced Management: CLNN's management team is considered experienced (3.1 years average tenure).
Experienced Board: CLNN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CLNN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.
Clene Inc.'s employee growth, exchange listings and data sources
- Name: Clene Inc.
- Ticker: CLNN
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$230.512m
- Shares outstanding: 63.50m
- Website: https://clene.com
Number of Employees
- Clene Inc.
- 6550 South Millrock Drive
- Suite G50
- Salt Lake City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.